{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:46:25Z","timestamp":1793310385310,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Eosinophilic esophagitis is a newly recognized entity, in which there is significant evidence available that clearly demonstrates the positive impact of PPIs on reducing esophageal eosinophilia in individuals across different age groups, including children, adolescents, and adults. Multiple mechanisms have been proposed to explain how this treatment effect occurs. In Brazil, there seems to be a lack of studies that have prospectively assessed the clinical and therapeutic response rate in pediatric patients with EoE. The objective of this study was to prospectively evaluate the clinical and therapeutic response of pediatric patients with EoE in a medical center located in southern Brazil, by investigating the effectiveness of PPI treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a clinical, prospective, open trial that took place in a pediatric hospital located in southern Brazil. The focus of the study was on patients diagnosed with Eosinophilic Esophagitis (EoE) who were given treatment using omeprazole\/esomeprazole at a dosage of 1\u2005mg.kg per dose, twice daily, for a period of 8\u201312 weeks. Following the treatment period, the patients underwent another endoscopy. Patients who exhibited 15 or less eosinophils in the biopsy conducted after the treatment were considered as responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 27 patients was evaluated (74.1% boys). The average age (\u00b1 standard deviation) was 8 years (\u00b14). Nineteen patients (70.3%) were considered as responders to PPI treatment: 6 patients\u201422.2%\u2014exhibited a complete response (defined as having 5 or fewer eosinophil per high power field. Additionally, 13 patients\u201448.1%\u2014demonstrated a partial response, characterized by eosinophil counts exceeding 5 but less than 15\u2005eos\/hpf. When comparing the responder and non-responder groups at presentation, a statistical difference was observed in the prevalence of food refusal as a presenting symptom. Food refusal was found to be more prevalent in the non-responder group (87.5% vs. 26.3%, <jats:italic>P<\/jats:italic>\u2009=\u20090.008). No differences were observed in terms of atopy history and endoscopic scores. Upon comparing the histological findings from the post-treatment endoscopy of the two groups, it was observed that PPI responders exhibited a greater tendency to decrease basal cell hyperplasia (<jats:italic>P<\/jats:italic>\u2009=\u20090.06) and intercellular edema (<jats:italic>P<\/jats:italic>\u2009=\u20090.08).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this group of pediatric patients with EoE in Southern Brazil most patients showed a high prevalence of histological, endoscopic, and clinical response to PPI treatment. PPIs showed efficacy in Brazilian patients with EoE, most of whom would probably not be able to adequately undergo other treatments.\n<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/ensaiosclinicos.gov.br\/rg\/RBR-2ntbth9<\/jats:ext-link>, identifier (U1111-1301-1842).<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2024.1346843","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T04:27:08Z","timestamp":1712550428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["High prevalence of response to PPI treatment in children and adolescents with eosinophilic esophagitis in southern Brazil"],"prefix":"10.3389","volume":"5","author":[{"given":"Luiza Salgado","family":"Nader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Epifanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Guimar\u00e3es","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Steinhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Melere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Soares","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Targa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"B1","first-page":"1022","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume-title":"Gastroenterology","author":"Dellon","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/MPG.0000000000001019","article-title":"High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia","volume":"62","author":"Guti\u00e9rrez-Junquera","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jpedp.2018.06.021","article-title":"Eosinophilic esophagitis\u2014where are we today?","volume":"95","author":"Ferreira","year":"2019","journal-title":"J Pediatr (Rio J)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16867","DOI":"10.34117\/bjdv9n5-157","article-title":"A preval\u00eancia da esofagite eosinof\u00edlica no Brasil\u2014uma revis\u00e3o da literatura","volume":"9","author":"Queiros","year":"2023","journal-title":"Braz J Dev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaci.2019.10.027","article-title":"Emerging therapies for eosinophilic esophagitis","volume":"145","author":"Greuter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cgh.2023.08.015","article-title":"Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MPG.0000000000003530","article-title":"Characterization of eosinophilic esophagitis from the European pediatric eosinophilic esophagitis registry (pEEr) of ESPGHAN","volume":"75","author":"Oliva","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B8","author":"Kliewer","year":"2023"},{"key":"B9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ped.2017.0779","article-title":"Adrenal insufficiency in pediatric eosinophilic esophagitis patients treated with swallowed topical steroids","volume":"30","author":"Hsu","year":"2017","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/JAA.S274524","article-title":"Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions","volume":"15","author":"Franciosi","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2018.00119","article-title":"The role of proton pump inhibitors in the management of pediatric eosinophilic esophagitis","volume":"6","author":"Guti\u00e9rrez-Junquera","year":"2018","journal-title":"Front Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1053\/j.gastro.2019.09.052","article-title":"Approaches and challenges to management of pediatric and adult patients with eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","article-title":"Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system","volume":"62","author":"Hirano","year":"2013","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/MPG.0000000000003660","article-title":"Proton pump inhibitor therapy in pediatric eosinophilic esophagitis: predictive factors and long-term step-down efficacy","volume":"76","author":"Guti\u00e9rrez-Junquera","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.18176\/jiaci.0230","article-title":"Eosinophilic esophagitis: treatment with different doses of omeprazole in children under 16 years","volume":"28","author":"G\u00f3mez Torrijos","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.13441","article-title":"Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies","volume":"43","author":"Arias","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jpedsurg.2012.11.006","article-title":"Eosinophilic esophagitis: is it also a surgical disease?","volume":"48","author":"Rea","year":"2013","journal-title":"J Pediatr Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MPG.0000000000001952","article-title":"Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis","volume":"67","author":"Guti\u00e9rrez-Junquera","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.cgh.2019.08.055","article-title":"Persistent basal cell hyperplasia is associated with clinical and endoscopic findings in patients with histologically inactive eosinophilic esophagitis","volume":"18","author":"Whelan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.15403\/jgld-4746","article-title":"Effect of proton pump inhibitor treatment in \u201cPPI non-responsive patients with eosinophilic esophagitis","volume":"32","author":"Thakk","year":"2023","journal-title":"J Gastrointestin Liver Dis"},{"key":"B22","author":"Sayej","year":"2009"},{"key":"B23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpeds.2008.07.042","article-title":"Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia","volume":"154","author":"Dranove","year":"2009","journal-title":"J Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/apt.15957","article-title":"Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry","volume":"52","author":"Laserna-Mendieta","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cgh.2010.09.019","article-title":"Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults","volume":"9","author":"Molina-Infante","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/ajg.2013.363","article-title":"Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study","volume":"108","author":"Dellon","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/apt.12636","article-title":"Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings","volume":"39","author":"Moawad","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/MEG.0000000000000331","article-title":"PPI-responsive esophageal eosinophilia cannot be distinguished from eosinophilic esophagitis by endoscopic signs","volume":"27","author":"Warners","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.gie.2019.11.031","article-title":"Correlation of endoscopic signs and mucosal alterations in children with eosinophilic esophagitis","volume":"91","author":"Hiremath","year":"2020","journal-title":"Gastrointest Endosc"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1346843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T04:27:10Z","timestamp":1712550430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1346843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":29,"alternative-id":["10.3389\/falgy.2024.1346843"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1346843","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"article-number":"1346843"}}